Thryv Therapeutics Inc. announces $30 million Series B financing led by InClin, Inc. to support the ASPIRE-HF study for heart failure.
PRIVATENov 03, 2026
Amount Raised
$30 Million
Round Type
Series B
San FranciscoBiotechnologyHealth CareTherapeutics
Investors
Alexandria Venture InvestmentsCTI Life Sciences FundadMare BioInnovationsLumira VenturesInvestissement QuébecAmplitude VenturesFonds De Solidarité FtqInClin, Inc.
Description
Thryv Therapeutics Inc. completed a $30 million Series B financing led by InClin, Inc. and supported by existing investors. The funds will be used for the ASPIRE-HF study in patients with heart failure
Who to call at Thryv Therapeutics, and when
A new round usually means Thryv Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Thryv Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Thryv Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Thryv Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Thryv Therapeutics
Location
San Francisco, California, United States
About
Thryv Therapeutics Inc. is a clinical-stage biotechnology company focused on developing precision therapies for inherited channelopathies and cardiometabolic diseases. Their pipeline includes highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). Thryv is advancing its lead candidate, THRV-1268, in clinical studies targeting heart failure and Long QT Syndrome.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Thryv Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnologyHealth CareTherapeutics